Shanghai LIDE Biotechnology Co., Ltd. ("Shanghai LIDE"), is committed to translational medicine and precision medical research of cancer, provide drug treatment guides to physicians, and proposing personalized treatment plans. The key technology platform is three functional diagnostics recommended by NCI: MINI PDX/PDX (Patient Derived Xenograft); CR (Conditional Reprogramming Cells) and Organoid. OncoVee® MINI PDX is company patented technology, a 7 days in vitro drug sensitivity test that can be used at pre-clinical for drug screening as well as translational use at clinic for personalized medicine.
The company owns AAALAC accredited SPF level animal centers and world-class equipment. Shanghai LIDE has two wholly-owned subsidiaries, "Xi'an LIDE Biotechnology Co., Ltd." and "Shanghai LIWEN Diagnostics" (hereinafter referred to as "Shanghai LIWEN") both with qualification of clinical testing laboratory. Shanghai LIDE was listed on the "New OTC Market" in August 2016 (stock code: 838848),